| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Virology, Faculty of Medicine, Imperial College London, St Mary's Campus, Norfolk Place, London W2 1PG, UK
Correspondence
Geoffrey L. Smith
glsmith{at}imperial.ac.uk
Vaccinia-immune globulin (VIG) was used to treat severe complications of smallpox vaccination, but its use was controversial because it resolved disease in only some clinical cases. VIG is a pool of hyperimmune sera collected from individuals with a high neutralizing titre against the intracellular mature form (IMV) of vaccinia virus (VACV), but activity against the extracellular enveloped form (EEV) was often not considered. Here, the efficacy of anti-VACV antibodies (Abs) in protecting mice from intranasal infection with the VACV strain Western Reserve (WR) was evaluated. Mice were immunized passively with hyperimmune rabbit Abs (IgG) generated against inactivated IMV or produced following infection by VACV; subsequently, animals were challenged with VACV WR. The results demonstrated that: (i) good protection requires Abs to EEV in addition to IMV; (ii) Abs were effective when given before or up to 4 days after infection; and (iii) protection of mice from VACV WR correlated with a reduction of virus replication in lungs, but not in brain. In agreement with studies conducted before smallpox was eradicated and recent studies using EEV antigens for immunization, this study reiterates the importance of anti-EEV Abs in protecting against orthopoxvirus infection and illustrates the need to evaluate both anti-IMV and anti-EEV neutralizing Abs in VIG.
A supplementary table and figure are available in JGV Online.
Present address: Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
This article has been cited by other articles:
|
|
 |
|
  C. N. Fogg, J. L. Americo, P. L. Earl, W. Resch, L. Aldaz-Carroll, R. J. Eisenberg, G. H. Cohen, and B. Moss Disparity between Levels of In Vitro Neutralization of Vaccinia Virus by Antibody to the A27 Protein and Protection of Mice against Intranasal Challenge J. Virol., August 15, 2008; 82(16): 8022 - 8029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Berhanu, R. L. Wilson, D. L. Kirkwood-Watts, D. S. King, T. K. Warren, S. A. Lund, L. L. Brown, A. K. Krupkin, E. VanderMay, W. Weimers, et al. Vaccination of BALB/c Mice with Escherichia coli-Expressed Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus Challenge J. Virol., April 1, 2008; 82(7): 3517 - 3529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Chen, P. Earl, J. Americo, I. Damon, S. K. Smith, F. Yu, A. Sebrell, S. Emerson, G. Cohen, R. J. Eisenberg, et al. Characterization of Chimpanzee/Human Monoclonal Antibodies to Vaccinia Virus A33 Glycoprotein and Its Variola Virus Homolog In Vitro and in a Vaccinia Virus Mouse Protection Model J. Virol., September 1, 2007; 81(17): 8989 - 8995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Garcia, C. A. Meseda, A. E. Mayer, A. Kumar, M. Merchlinsky, and J. P. Weir Characterization and Use of Mammalian-Expressed Vaccinia Virus Extracellular Membrane Proteins for Quantification of the Humoral Immune Response to Smallpox Vaccines Clin. Vaccine Immunol., August 1, 2007; 14(8): 1032 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Staib, Y. Suezer, S. Kisling, U. Kalinke, and G. Sutter Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara. J. Gen. Virol., October 1, 2006; 87(Pt 10): 2917 - 2921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tang, M. Murtadha, M. Schnell, L. C. Eisenlohr, J. Hooper, and P. Flomenberg Human T-cell responses to vaccinia virus envelope proteins. J. Virol., October 1, 2006; 80(20): 10010 - 10020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Law, G. C. Carter, K. L. Roberts, M. Hollinshead, and G. L. Smith From the Cover: Ligand-induced and nonfusogenic dissolution of a viral membrane PNAS, April 11, 2006; 103(15): 5989 - 5994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Chen, P. Earl, J. Americo, I. Damon, S. K. Smith, Y.-H. Zhou, F. Yu, A. Sebrell, S. Emerson, G. Cohen, et al. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus PNAS, February 7, 2006; 103(6): 1882 - 1887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Putz, I. Alberini, C. M. Midgley, I. Manini, E. Montomoli, and G. L. Smith Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy J. Gen. Virol., November 1, 2005; 86(11): 2955 - 2960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lustig, C. Fogg, J. C. Whitbeck, R. J. Eisenberg, G. H. Cohen, and B. Moss Combinations of Polyclonal or Monoclonal Antibodies to Proteins of the Outer Membranes of the Two Infectious Forms of Vaccinia Virus Protect Mice against a Lethal Respiratory Challenge J. Virol., November 1, 2005; 79(21): 13454 - 13462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Panchanathan, G. Chaudhri, and G. Karupiah Interferon function is not required for recovery from a secondary poxvirus infection PNAS, September 6, 2005; 102(36): 12921 - 12926. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
